Global Rosuvastatin Calcium Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rosuvastatin Calcium Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart attack and stroke.Rosuvastatin calcium is a hygroscopic powder suitable for the manufacture of tablets and capsules. The appropriate excipients need to be added. The particle size of the product is designed in such a way that optimal dissolution can be obtained (depending on formulation).
Rosuvastatin Calcium is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Rosuvastatin Calcium was developed by Shionogi and has been formulated into finished oral dosage form and marketedby AstraZeneca as Crestor, Abbott Laboratories as R2.
Rosuvastatin Calcium report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rosuvastatin Calcium market is projected to reach US$ 694.1 million in 2034, increasing from US$ 525.7 million in 2022, with the CAGR of 4.0% during the period of 2024 to 2034. Demand from Tablet (including dispersible tablet and general tablet) and Capsule are the major drivers for the industry.
In additional, EU is also the largest consumer of rosuvastatin calcium, about 34% of the global production was consumed in EU. China is the second producer with the market share of 28%. Top Three manufacturers in rosuvastatin calcium are AstraZeneca, MSN Laboratories, Changzhou Pharmaceutical Factory, according for 55% of the total amount.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Calcium market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Teva Pharmaceutical Industries
MSN Laboratories
Cadila Pharmaceuticals
LGM Pharma
Bal Pharma
Changzhou Pharmaceutical Factory
Jingxin Pharm
Zhejiang Hisun Pharmaceutical
HEC Pharm
Lunan Pharmaceutical
Nanjing Frochem Tech
Lianyungang Runzhong Pharmaceutical
Shandong Bechem Chemicals
CTX Life Sciences
Segment by Type
Purity 98.0%
Purity 99.0%
Other
Tablet (including dispersible tablet and general tablet)
Capsule
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Rosuvastatin Calcium market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rosuvastatin Calcium, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rosuvastatin Calcium industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rosuvastatin Calcium in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rosuvastatin Calcium introduction, etc. Rosuvastatin Calcium Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rosuvastatin Calcium market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Rosuvastatin Calcium is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Rosuvastatin Calcium was developed by Shionogi and has been formulated into finished oral dosage form and marketedby AstraZeneca as Crestor, Abbott Laboratories as R2.
Rosuvastatin Calcium report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rosuvastatin Calcium market is projected to reach US$ 694.1 million in 2034, increasing from US$ 525.7 million in 2022, with the CAGR of 4.0% during the period of 2024 to 2034. Demand from Tablet (including dispersible tablet and general tablet) and Capsule are the major drivers for the industry.
In additional, EU is also the largest consumer of rosuvastatin calcium, about 34% of the global production was consumed in EU. China is the second producer with the market share of 28%. Top Three manufacturers in rosuvastatin calcium are AstraZeneca, MSN Laboratories, Changzhou Pharmaceutical Factory, according for 55% of the total amount.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Calcium market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Teva Pharmaceutical Industries
MSN Laboratories
Cadila Pharmaceuticals
LGM Pharma
Bal Pharma
Changzhou Pharmaceutical Factory
Jingxin Pharm
Zhejiang Hisun Pharmaceutical
HEC Pharm
Lunan Pharmaceutical
Nanjing Frochem Tech
Lianyungang Runzhong Pharmaceutical
Shandong Bechem Chemicals
CTX Life Sciences
Segment by Type
Purity 98.0%
Purity 99.0%
Other
Segment by Application
Tablet (including dispersible tablet and general tablet)
Capsule
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Rosuvastatin Calcium market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rosuvastatin Calcium, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rosuvastatin Calcium industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rosuvastatin Calcium in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rosuvastatin Calcium introduction, etc. Rosuvastatin Calcium Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rosuvastatin Calcium market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices